Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Aug 30;220(7):1127-1135.
doi: 10.1093/infdis/jiz241.

Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults

Scott A Halperin  1 , Rituparna Das  2 , Matthew T Onorato  2 , Kenneth Liu  2 , Jason Martin  2 , Rebecca J Grant-Klein  2 , Rick Nichols  3 , Beth-Ann Coller  2 , Frans A Helmond  2 , Jakub K Simon  2 ; V920-012 Study Team
Affiliations
Clinical Trial

Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults

Scott A Halperin et al. J Infect Dis. .

Abstract

Background: This double-blind study assessed immunogenicity, lot consistency, and safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVΔG-ZEBOV-GP).

Methods: Healthy adults (N = 1197) were randomized 2:2:2:2:1 to receive 1 of 3 consistency lots of rVSVΔG-ZEBOV-GP (2 × 107 plaque-forming units [pfu]), high-dose 1 × 108 pfu, or placebo. Antibody responses pre-/postvaccination (28 days, 6 months; in a subset [n = 566], months 12, 18, and 24) were measured. post hoc analysis of risk factors associated with arthritis following vaccination was performed.

Results: ZEBOV-GP enzyme-linked immunosorbent assay (ELISA) geometric mean titers (GMTs) increased postvaccination in all rVSVΔG-ZEBOV-GP groups by 28 days (>58-fold) and persisted through 24 months. The 3 manufacturing lots demonstrated equivalent immunogenicity at 28 days. Neutralizing antibody GMTs increased by 28 days in all rVSVΔG-ZEBOV-GP groups, peaking at 18 months with no decrease through 24 months. At 28 days, ≥94% of vaccine recipients seroresponded (ZEBOV-GP ELISA, ≥2-fold increase, titer ≥200 EU/mL), with responses persisting at 24 months in ≥91%. Female sex and a history of arthritis were identified as potential risk factors for the development of arthritis postvaccination.

Conclusions: Immune responses to rVSVΔG-ZEBOV-GP persisted to 24 months. Immunogenicity and safety results support continued rVSVΔG-ZEBOV-GP development.

Clinical trials registration: NCT02503202.

Keywords: Ebola; clinical trial; immunogenicity; rVSVΔG-ZEBOV-GP; vaccine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Participant disposition.
Figure 2.
Figure 2.
Antibody responses through 24 months postvaccination by ZEBOV-GP ELISA (A and B) and PRNT (C and D) GMTs (A and C) and seroresponse rates (B and D) in the per-protocol immunogenicity population. N = Number of participants with serology data at 1 or more timepoints according to the treatment to which they were randomized. n = Number of participants contributing to the analysis. Values below the LLOQ (ZEBOV-GP ELISA: <36.11; PRNT: <35) were replaced with ½ LLOQ in GMT calculations. Abbreviations: CI, confidence interval; GMT, geometric mean titer; LLOQ, lower limit of quantification; PRNT, plaque reduction neutralization test; rVSVΔG-ZEBOV-GP, recombinant vesicular stomatitis virus–Zaire Ebola virus envelope glycoprotein vaccine; ZEBOV-GP ELISA, Zaire Ebola virus envelope immunoglobulin G glycoprotein enzyme-linked immunosorbent assay.
Figure 3.
Figure 3.
ZEBOV-GP ELISA (A) and PRNT (B) GMFR by vaccination group in the per-protocol immunogenicity population. Error bars represent 95% CI. The per-protocol immunogenicity population includes all participants who were compliant with the protocol, received vaccination, were seronegative at day 1, and had a serum sample at 1 or more timepoints collected within an acceptable day range. N = Number of participants with serology data at 1 or more timepoints according to the treatment to which they were randomized. n = Number of participants contributing to the analysis. Values below the LLOQ (ZEBOV-GP ELISA: <36.11; PRNT: <35) were replaced with ½ LLOQ in GMT calculations. Abbreviations: CI, confidence interval; GMFR, geometric mean fold rise; GMT, geometric mean titer; LLOQ, lower limit of quantification; PRNT, plaque reduction neutralization test; rVSVΔG-ZEBOV-GP, recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine; ZEBOV-GP ELISA, Zaire Ebola virus envelope glycoprotein immunoglobulin G enzyme-linked immunosorbent assay.
See this image and copyright information in PMC

References

    1. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377:849–62. - PMC - PubMed
    1. WHO Ebola Response Team. After Ebola in West Africa—unpredictable risks, preventable epidemics. N Engl J Med 2016; 375:587–96. - PubMed
    1. World Health Organization. Ebola virus disease. http://www.who.int/ebola/en/. Accessed 17 April 2019.
    1. Centers for Disease Control and Prevention. History of Ebola virus disease. https://www.cdc.gov/vhf/ebola/outbreaks/history/summaries.html. Accessed 17 April 2019.
    1. Garbutt M, Liebscher R, Wahl-Jensen V, et al. . Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458–65. - PMC - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources